title: Visual acuity and electroretinography findings 3 ½ years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity.
authors.forename: Parag K
authors.initials: PK
authors.lastname: Shah
authors.forename: Rodney J
authors.initials: RJ
authors.lastname: Morris
authors.forename: V
authors.initials: V
authors.lastname: Narendran
authors.forename: N
authors.initials: N
authors.lastname: Kalpana
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004596:Electroretinography; D006801:Humans; D007231:Infant, Newborn; D058449:Intravitreal Injections; D008297:Male; D012178:Retinopathy of Prematurity / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D012720:Severity of Illness Index; D013997:Time Factors; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab